Artiva CMO sells 8,222 shares after option exercise

Q: What insider transactions did ARTV’s Chief Medical Officer report on this Form 4?

Subhashis Banerjee exercised 5,306 stock options at $1.92 per share into common stock and sold 8,222 common shares at a weighted average of $12.0087 per share on August 27, 2026, under a Rule 10b5-1 trading plan.

Q: How many ARTV shares did the insider sell and at what price?

On August 27, 2026, Subhashis Banerjee sold 8,222 shares of Artiva Biotherapeutics common stock at a weighted average sale price of $12.0087 per share, with individual sale prices ranging from $12.00 to $12.05, inclusive.

Q: How many ARTV options did the insider exercise and at what strike price?

Subhashis Banerjee exercised 5,306 Employee Stock Options with an exercise price of $1.92 per share, receiving 5,306 shares of Artiva Biotherapeutics common stock on August 27, 2026.

Q: What is the vesting schedule of the ARTV stock options involved?

For the option referenced, 25% of the shares vested and became exercisable on April 8, 2026. The remaining shares vest and become exercisable at a rate of 1/36th per month over the following 36 months.

Artiva Biotherapeutics, Inc. (ARTV) reported insider transactions by Chief Medical Officer Subhashis Banerjee on August 27, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported insider transactions by Chief Medical Officer Subhashis Banerjee on August 27, 2026. Banerjee exercised 5,306 stock options at $1.92 per share to acquire the same number of common shares, then sold 8,222 common shares at a weighted average of $12.0087 per share. The option exercise left 74,265 options outstanding and was carried out under a Rule 10b5-1 trading plan adopted on May 14, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Banerjee Subhashis

Role Chief Medical Officer

Sold 8,222 shs ($99K)

Approx. gross sale proceeds $99K

Approx. exercise cost $10K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy) ^{F1, F3}	5,306	$0.00	$0.00
Exercise	Common Stock ^F1	5,306	$1.92	$10K
Sale	Common Stock ^{F1, F2}	8,222	$12.0087	$99K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 74,265 contracts (Direct); Common Stock — 142,047 shares (Direct)

Footnotes (3)

F1. The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.
F2. The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3. 25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months.

Key Figures

Shares sold: 8,222 shares of Common Stock Weighted average sale price: $12.0087 per share Options exercised: 5,306 Employee Stock Options +5 more

8 metrics

Shares sold 8,222 shares of Common Stock Sale on August 27, 2026

Weighted average sale price $12.0087 per share Common Stock sale on August 27, 2026; prices ranged $12.00–$12.05

Options exercised 5,306 Employee Stock Options Exercised into Common Stock on August 27, 2026

Option exercise price $1.92 per share Exercise of 5,306 Employee Stock Options

Options outstanding after transaction 74,265 options Employee Stock Options following the reported exercise

Rule 10b5-1 Plan adoption date May 14, 2026 Plan under which the reported transactions occurred

Option vesting cliff 25% Portion vested on April 8, 2026 for the reported option

Ongoing vesting rate 1/36th per month Remaining shares vest over the following 36 months

Key Terms

Rule 10b5-1 Plan, Employee Stock Option, weighted average sale price, vesting, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Employee Stock Option financial

"security_title": "Employee Stock Option (Right to Buy)""

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $12.0087"

vesting financial

"shares initially subject to the option vested and became exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

FAQ

What insider transactions did ARTV’s Chief Medical Officer report on this Form 4?

Subhashis Banerjee exercised 5,306 stock options at $1.92 per share into common stock and sold 8,222 common shares at a weighted average of $12.0087 per share on August 27, 2026, under a Rule 10b5-1 trading plan.

How many ARTV shares did the insider sell and at what price?

On August 27, 2026, Subhashis Banerjee sold 8,222 shares of Artiva Biotherapeutics common stock at a weighted average sale price of $12.0087 per share, with individual sale prices ranging from $12.00 to $12.05, inclusive.

How many ARTV options did the insider exercise and at what strike price?

Subhashis Banerjee exercised 5,306 Employee Stock Options with an exercise price of $1.92 per share, receiving 5,306 shares of Artiva Biotherapeutics common stock on August 27, 2026.

How many ARTV options does the insider hold after these transactions?

Following the reported option exercise, Subhashis Banerjee holds 74,265 Employee Stock Options related to Artiva Biotherapeutics common stock, as reported in the filing.

Were ARTV insider transactions made under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported transactions occurred under a Rule 10b5-1 Plan adopted by Subhashis Banerjee on May 14, 2026, and the Rule 10b5-1 checkbox for the filing is marked true.

What is the vesting schedule of the ARTV stock options involved?

For the option referenced, 25% of the shares vested and became exercisable on April 8, 2026. The remaining shares vest and become exercisable at a rate of 1/36th per month over the following 36 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/31/2026 - 07:07 PM Accepted by SEC EDGAR 08/31/2026 - 07:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Banerjee Subhashis

(Last)

(First)

(Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/27/2026		M⁽¹⁾		5,306	A	$1.92	150,269	D
Common Stock	08/27/2026		S⁽¹⁾		8,222	D	$12.0087⁽²⁾	142,047	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Buy)	$1.92	08/27/2026		M⁽¹⁾			5,306	⁽³⁾	04/07/2035	Common Stock	5,306	$0	74,265	D

Explanation of Responses:

1. The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

2. The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. 25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months.

	/s/ Andrew Cronauer, Attorney-in-Fact	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR